Phase I Maximal Use Pharmacokinetic Study of Tirbanibulin Ointment 1% in Subjects with Actinic Keratosis

Main Article Content

Regina Yavel
J. Scott Overcash
Jay Zhi
Eva Cutler
David Cutler
Jane Fang

Keywords

Skin Cancer, Actinic Keratosis, Src Kinase Inhibitor, Tirbanibulin

Abstract

Abstract not available.

References

1. Smolinksi MP, et al J Med Chem 2018 61 4707 4719

2. DuBois J, et al Phase I study of tirbanibulin ointment 1 a novel Src phosphorylation and tubulin polymerization inhibitor, in subjects with actinic keratosis Poster presented at the 6 th Annual Practical Symposium, Beaver Creek, CO, USA, August 8 11 2019

3. DuBois J, et al Phase II study of tirbanibulin ointment 1 a novel Src phosphorylation and tubulin polymerization inhibitor, for actinic keratosis Poster presented at the 6 th Annual Practical Symposium, Beaver Creek, CO, USA, August 8 11 2019

4. Blauvelt A, et al Tirbanibulin ointment 1 for actinic keratosis(AK) Results from two Phase 3 studies with 1 year follow up Poster presented at the Maui Derm Virtual Congress, June 24 27 2020

Most read articles by the same author(s)